Login to Your Account



DYNAMO down: Underwhelming data endanger Infinity's Abbvie deal

By Marie Powers
News Editor

Tuesday, June 14, 2016

Infinity Pharmaceuticals Inc. stunned investors early Tuesday by disclosing disappointing results from the registration-focused DYNAMO study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription